Expanded capacity in Nansha, China will support mid-scale manufacturing to ensure a smooth transition between early-phase and large-scale commercial production
This is the second line opened this year for parenteral drug product clinical and commercial manufacturing, with an annual capacity of 10 million units
The company does not believe that the warning letter will have an impact on disruption of supplies or the existing revenues from operations of this facility
The new plant will include a wide range of dosage form capabilities for oral solids, liquids, topicals, films, and manufacturing technologies for granulation, film coating, spray drying, tableting
This win is on the back of a prestigious order from Reliance Life Sciences
Construction is now underway with the facility scheduled to be operational by 2025
Investment further strengthens Merck's "Big 3," the key drivers for increasing Group sales to approximately € 25 billion by 2025
Dr. Mahdavi will lead Ginkgo's commercial efforts in the growing areas of bio-reagents, cell and gene therapies and new biopharmaceutical modalities.
The Board also decided that Auro Vaccines will explore the possibilities of offering contract manufacturing to global vaccine developers
With the receipt of the EIR, the inspection stands successfully closed.
Subscribe To Our Newsletter & Stay Updated
